Literature DB >> 28135725

Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.

Amir Qaseem1, Timothy J Wilt1, Robert Rich1, Linda L Humphrey1, Jennifer Frost1, Mary Ann Forciea1, Nick Fitterman, Michael J Barry, Carrie A Horwitch, Alfonso Iorio, Robert M McLean.   

Abstract

Description: The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) jointly developed this guideline to present the evidence and provide clinical recommendations based on the benefits and harms of higher versus lower blood pressure targets for the treatment of hypertension in adults aged 60 years or older.
Methods: This guideline is based on a systematic review of published randomized, controlled trials for primary outcomes and observational studies for harms only (identified through EMBASE, the Cochrane Database of Systematic Reviews, MEDLINE, and ClinicalTrials.gov), from database inception through January 2015. The MEDLINE search was updated through September 2016. Evaluated outcomes included all-cause mortality, morbidity and mortality related to stroke, major cardiac events (fatal and nonfatal myocardial infarction and sudden cardiac death), and harms. This guideline grades the evidence and recommendations using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes all adults aged 60 years or older with hypertension. Recommendation 1: ACP and AAFP recommend that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events. (Grade: strong recommendation, high-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient. Recommendation 2: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in adults aged 60 years or older with a history of stroke or transient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for recurrent stroke. (Grade: weak recommendation, moderate-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient. Recommendation 3: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for stroke or cardiac events. (Grade: weak recommendation, low-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28135725     DOI: 10.7326/M16-1785

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  78 in total

1.  Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies.

Authors:  Yun Zhang; Mingming Liang; Chenyu Sun; Guangbo Qu; Tingting Shi; Min Min; Yile Wu; Yehuan Sun
Journal:  J Hum Hypertens       Date:  2019-07-30       Impact factor: 3.012

Review 2.  Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients.

Authors:  Ian A Scott; Sarah N Hilmer; David G Le Couteur
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

3.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  J Spinal Cord Med       Date:  2019-06-10       Impact factor: 1.985

4.  Small Target Group.

Authors:  Til Uebel
Journal:  Dtsch Arztebl Int       Date:  2019-02-01       Impact factor: 5.594

5.  The chronotherapy of hypertension: or the benefit of taking blood pressure tablets at bedtime.

Authors:  Gervase Vernon
Journal:  Br J Gen Pract       Date:  2017-04       Impact factor: 5.386

6.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018

Review 7.  Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines.

Authors:  Bethany Roehm; Daniel E Weiner
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

Review 8.  Comparison of the 2017 ACC/AHA Hypertension Guideline with Earlier Guidelines on Estimated Reductions in Cardiovascular Disease.

Authors:  Joshua D Bundy; Katherine T Mills; Jiang He
Journal:  Curr Hypertens Rep       Date:  2019-08-31       Impact factor: 5.369

9.  Disparities in Hypertension Control Across and Within Three Health Systems Participating in a Data-Sharing Collaborative.

Authors:  Kevin Selby; Martha Michel; Ginny Gildengorin; Leah Karliner; Rajiv Pramanik; Valy Fontil; Michael B Potter
Journal:  J Am Board Fam Med       Date:  2018 Nov-Dec       Impact factor: 2.657

Review 10.  Hypertension Management in Nursing Homes: Review of Evidence and Considerations for Care.

Authors:  Michelle Vu; Loren J Schleiden; Michelle L Harlan; Carolyn T Thorpe
Journal:  Curr Hypertens Rep       Date:  2020-01-14       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.